Global Myelodysplastic Syndrome Therapeutics Market 2018-2022
About Myelodysplastic Syndrome Therapeutics
Myelodysplastic syndrome (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenia due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to AML.
Technavio’s analysts forecast the global myelodysplastic syndrome therapeutics market to grow at a CAGR of 2.54% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of patented and generic drugs used to treat MDS.
The market is divided into the following segments based on geography:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook